Publication Name	World Journal of Virology
Manuscript ID	61435
Country	Italy

Received	2020-12-12 16:10
Peer-Review Started	2020-12-12 16:12
To Make the First Decision
Return for Revision	2021-01-27 07:45
Revised	2021-01-28 19:42
Second Decision	2021-02-24 06:30
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2021-03-08 19:51
Articles in Press	2021-03-08 19:51
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-03-13 08:05
Publish the Manuscript Online	2021-03-16 09:17

ISSN	2220-3249 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Minireviews
Article Title	Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID 19 compared with standard of care? A literature review
Manuscript Source	Invited Manuscript
All Author List	Anna Maria Spera
ORCID	Author(s) ORCID Number Anna Maria Spera http://orcid.org/0000-0003-1292-3040
Funding Agency and Grant Number
Corresponding Author	Anna Maria Spera, MD, Doctor, Doctor, Infectious Diseases, University of Study of Salerno, Largo Ippocrate, Salerno 84131, Italy. annamariaspera@hotmail.it
Key Words	COVID 19; SARS-CoV-2; Pandemic; Nucleotide inhibitors; Sofosbuvir; Coronavirus
Core Tip	Coronavirus disease 2019 represents a terrible, still unsolved, global problem affecting not only the healthcare system but also the economic and social one. All countries are facing and fighting against this pandemic but there is still no specific treatment for its eradication. Recently some nucleotide inhibitors, already approved and employed for the treatment of hepatitis c virus infection, have been repurposed for treatment of severe acute respiratory syndrome coronavirus 2 infection, because of some common features among coronaviruses and hepatitis c virus. Herein briefly I focused on the effects of this compound on coronavirus disease 2019, based on its pharmacokinetic properties and on results of several completed clinical trials.
Publish Date	2021-03-16 09:17
Citation	Spera AM. Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID 19 compared with standard of care? A literature review. World J Virol 2021; 10(2): 53-61
URL	https://www.wjgnet.com/2220-3249/full/v10/i2/53.htm
DOI	https://dx.doi.org/10.5501/wjv.v10.i2.53

Full Article (PDF)	WJV-10-53.pdf
Full Article (Word)	WJV-10-53.docx
Manuscript File	61435_Auto_Edited_LM.docx
Answering Reviewers	61435-Answering reviewers.pdf
Audio Core Tip	61435-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	61435-Conflict-of-interest statement.pdf
Copyright License Agreement	61435-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	61435-Language certificate.pdf
Peer-review Report	61435-Peer-review(s).pdf
Scientific Misconduct Check	61435-Bing-Wang JL-1.jpg
Scientific Misconduct Check	61435-Scientific misconduct check.pdf
Scientific Editor Work List	61435-Scientific editor work list.pdf
CrossCheck Report	61435-CrossCheck report.pdf